Device type · NTI
Drug Metabolizing Enzyme Genotyping Systems
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
NTI
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Drug Metabolizing Enzyme Genotyping Systems
- Product code
- NTI
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3360
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for NTI
Latest FDA decisions
K220026 · Decided Mar 21, 2023 · 440 days after receipt
Device type: Drug Metabolizing Enzyme Genotyping Systems (NTI) · Laboratory Medicine & Pathology
- xTAG CYP2D6 Kit v3510(k)
Luminex Molecular Diagnostics, Inc.
K170492 · Decided Aug 11, 2017 · 175 days after receipt
Device type: Drug Metabolizing Enzyme Genotyping Systems (NTI) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2559-2014 · Started Mar 18, 2014 · Posted by FDA Aug 28, 2014
Reason given: Nanosphere has recieved reports related to an unacceptable increase in initial no-call rate when performing the Verigene CYP2C19 Nucleic Acid Test (2C19), which has been confirmed through internal testing.
Cause as FDA categorized it: Under Investigation by firm
Z-3112-2011 · Started May 24, 2011 · Posted by FDA Aug 31, 2011
Reason given: Inaccurate test results, due to possible defective primers, which could lead to incorrect dosage on manufactured drug assays.
Cause as FDA categorized it: Other
Z-0734-2007 · Started Mar 9, 2007 · Posted by FDA Apr 11, 2007
Reason given: The current package insert for the AmpliChip CYP 450 test, lists an incorrect part number for DNase I. The DNase is listed in the "Other Materials Required" section as 'DNase I rec., RNase-free, P/N 04716728001 (Roche Applied Science)" . The Part Number listed for the DNase I listed is incorrect and of lower specific...
Cause as FDA categorized it: Other
1 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.